Ampio Pharmaceuticals, Inc.'s Unit Vyrix Files For $29 Million IPO To Develop Anti-Premature Ejaculation Drug

Ampio Pharmaceuticals’ Vyrix Files Registration Statement for Proposed Initial Public Offering

GREENWOOD VILLAGE, Colo., April 21, 2014 /PRNewswire/ -- Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Vyrix. Vyrix has applied for a listing of its common stock on the NYSE MKT under the symbol “VYRX”.

Aegis Capital Corp. is acting as sole book-running manager for the offering. Fordham Financial is acting as co-manager for the offering. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com.

This announcement is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933. The registration statement on Form S-1 filed with the SEC has not yet become effective and shares may not be sold nor may offers to buy be accepted prior to the time when the registration statement becomes effective. Copies of the registration statement can be accessed through the Commission’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Logo - http://photos.prnewswire.com/prnh/20120516/MM09116LOGO

SOURCE Ampio Pharmaceuticals Inc.

Help employers find you! Check out all the jobs and post your resume.